| Document |
Document Title |
|
WO/2007/091716A1 |
An optical film, which has been subjected to an orientation treatment, containing a low-molecular weight compound, in which a birefringence Δn(550 nm) is larger than zero (0) in an orientation direction, and the optical film satisfies t...
|
|
WO/2007/068745A1 |
The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R'1, -A-R'1 group, R'1 being selected among - COOH, -COOR3, -CONH2, -CONHR3, -CONR3 R4, -CHO, -CH2OH, -CH2OR5, and A represents a C2-C16 alkyl...
|
|
WO2006119758B1 |
The invention relates to dihydroxyphenylalanine derivatives, the production thereof, and pharmaceutical compositions containing said dihydroxyphenylalanine derivatives. The invention further relates to the use of said dihydroxyphenylalan...
|
|
WO/2007/049736A1 |
This invention provides a process for producing a natural product having stable quality with high recovery. There is also provided a method for concentration-crystallizing a natural product, characterized by comprising continuously measu...
|
|
WO/2007/049658A1 |
A dithianedithiol derivative represented by the following general formula (1): (wherein R represents hydrogen or acyl; and X represents a C1-12 divalent hydrocarbon group which may have a substituent not participating in reactions and ma...
|
|
WO/2007/035735A1 |
The invention features compositions comprising at least one monomer that comprises a cyclic dithiane moiety attached to a (meth)acryloyl moiety. The composition may optionally contain additional polymerizable compounds, such as ethylenic...
|
|
WO/2007/032362A1 |
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as...
|
|
WO/2007/015412A1 |
Disclosed is an organic electroluminescent device (organic EL device) of simple structure which is improved in luminous efficiency and sufficiently secured in driving stability. Also disclosed is a heterocyclic compound used for such an ...
|
|
WO/2006/134282A1 |
The invention concerns a cosmetic, therapeutic, in particular dermatological, bioprecursor of formula [A]n -PP - [B]m wherein: PP represents a polyphenol radical where each hydroxyl function is protected by a group A or a group B; A is a...
|
|
WO/2006/134489A1 |
The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) derivatives of sulindac, for the treatment/prevention, alone or in combination, of cancer.
|
|
WO/2006/125295A1 |
The present invention provides new derivatives of 4-or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4-or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal disea...
|
|
WO/2006/126415A1 |
A sulfur-containing cycloolefin resin of 1000 to 1,000,000 weight average molecular weight comprised of any of units of the general formula (1): wherein each of R1 to R6 independently is a hydrogen atom, a C1-C20 alkyl, a C1-C20 aralkyl,...
|
|
WO/2006/125293A1 |
The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal dis...
|
|
WO/2006/117995A1 |
A therapeutic agent for loss of scalp hair comprising a lipoic acid or a lipoic acid derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient: (1) wherein R represents an OH group, a...
|
|
WO/2006/111791A1 |
The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) that release hydrogen sulfide (H2S). The present invention also provides methods for treating, preventing and/or reducing inflammation-associated d...
|
|
WO/2006/110221A1 |
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...
|
|
WO/2006/100229A1 |
Process for purifying thioctic acid in water comprising the following steps: a) dissolving the thioctic acid in an aqueous alkaline solution or alternatively dissolving a thioctic acid salt, if necessary adjusting the pH to alkaline valu...
|
|
WO2005075453A9 |
A novel linker compound that minimizes any nonspecific hydrophobic interactions and is capable of easily regulating the length to disulfide group subjected to metal bond to thereby enable efficient formation of metal-sulfur bond; a novel...
|
|
WO/2006/089861A2 |
The invention relates to dithiolethiones derivatives as monoamino oxidase inhibitors, in particular MAO-B inhibitors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said dithiolet...
|
|
WO/2006/085510A1 |
A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the ...
|
|
WO/2006/066894A1 |
Compounds of general formula (I), wherein R’, R, x and z have the meaning reported in the specification, are useful for treating inflammatory diseases including metabolic syndrome, diabetes, obesity, dyslipidemia, and insulin resistance.
|
|
WO/2006/048911A2 |
Compositions to be incorporated in products with hypoglycemizing, anti-oxidant, vasoprotective and anti-hyperlipemic activity, or in products recommended for the treatment of anaemias and states or iron deficiency, the compositions being...
|
|
WO/2006/047011A2 |
Fuels, especially hydrocarbon fuels, and lubricants, especially lubricating oils, contain a class of anti-corrosion, anti-wear, anti-fatigue, and extreme pressure additives that are derived from 1,3-dithiolane-2-thiones.
|
|
WO/2006/044379A2 |
The present invention relates to compounds capable of acting as androgen receptor, antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agen...
|
|
WO/2006/029532A1 |
Nitrate esters and methods for mitigating neurodegeneration, affecting neuroprotection, affecting cognition enhancement, and/or preventing or mitigating tissue and/or cellular damage in a subject are described. Neurological or cognitive ...
|
|
WO/2006/021282A1 |
The invention relates to novel compounds containing at least one multiple bond that is excited by irradiation with polarised light and thus produces an anisotropy in films containing said compounds or amplifies an already existing anisot...
|
|
WO/2006/021413A1 |
The present invention relates to novel &agr -keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular ...
|
|
WO/2006/014219A2 |
A process for the manufacture of new stable, crystalline salts of N-[2-(dimethylamino)-ethyl]-1,2-dithiolane-3-pentanamide (racemic and chiral forms) with good water solubility that are useful as antioxidant compounds and effectively inh...
|
|
WO/2005/095941A1 |
A mass analysis method for a derivative of an organic residue containing a sulfur atom, characterized in that it comprises ionizing a derivative of an organic residue containing said sulfur atom from a metal-organic residue composite whe...
|
|
WO/2005/085186A1 |
Disclosed is a method for producing an isocyanate compound through reaction between a carbonate of a corresponding amine compound and phosgene, wherein phosgene is introduced into an organic solvent solution of the carbonate of the amine...
|
|
WO/2005/079845A1 |
Preventives for migraine which contain, as the active ingredient, a double antagonist to 5-HT2B and 5-HT7 receptors having selective binding affinities for the 5-HT2B and 5-HT7 receptors. These preventives for migraine show a favorable p...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/079378A2 |
Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.
|
|
WO/2005/073184A1 |
The invention relates to substituted 1,3-diphenylprop-2-en-1-one derivative compounds, pharmaceutical and/or cosmetic compositions containing same, and the applications thereof in therapeutics and cosmetics. The invention also relates to...
|
|
WO/2005/068415A1 |
Disclosed is a phenylalanine derivative having excellent VLA-4 inhibitory activity which is represented by the following general formula (1) or a salt thereof. (1) (In the formula, R1 represents an aromatic hydrocarbon group having 6-10 ...
|
|
WO/2005/051941A1 |
A 1,2,4-triazole derivative of formula (1) or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.
|
|
WO/2005/049741A1 |
A method of forming a SAM on at least one surface of a substrate by application to said surface of a 2-mono-, or 2,2-disubstituted 1,3-dithiacyclopentane so as to form a SAM prepared therefrom on said surface.
|
|
WO/2005/043962A1 |
Disclosed is a charge-transporting organic material which contains a compound with a 1,4-dithiin ring which is represented by the formula (1) below. By using a thin film made of such a organic material in a small-molecule organic electro...
|
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
|
WO/2005/019159A1 |
A process for producing corresponding &agr -aminooxyketones in high yield and with high enantioselectivity, that is, a process for the production of optically active &agr -aminooxyketone derivatives represented by the general formula (1)...
|
|
WO/2004/099162A1 |
Compounds of Formula 8 are provided: A and B are each independently selected from the group consisting of -NO-, -SO-, and - NR9-. C is a single bond or a double bond. D is selected from the group consisting of single bond, E is selected ...
|
|
WO/2004/098582A2 |
The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds ...
|
|
WO/2004/094403A1 |
Salt of thioctic acid with L-carnitine with the formula: A Y (X)x where A is formula (I) where Y is the cation of an alkaline metal, of an alkaline earth metal or is a quaternary ammonium group, X is A or OH-, x is equal to 0 when Y is t...
|
|
WO/2004/092157A1 |
The invention relates to ammonium salts of &agr -liponic acid of general formula (I): (Lp) (A), formed from &agr -liponic acid (Lp) and amino compounds (A) of general formula (II) or general formula (III). The invention also relates to a...
|
|
WO/2004/089927A1 |
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases o...
|
|
WO/2004/078908A2 |
The present invention relates to novel &agr -keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular ...
|
|
WO/2004/077511A2 |
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...
|
|
WO/2004/069774A2 |
There is provided a method of producing novel 13C-labelled estrogen analogues. The method preferably proceeds via an intermediate A or B or which is a mixture of (A) or (B): wherein a 13C atom is located at one or more of positions 1, 2,...
|
|
WO/2004/060971A2 |
The present invention relates to sulfide-containing polythiols and their methods of preparation.Sulfide-containing polythiols can have a variety of uses and applications. The sulfide-containing polythiols of the present invention can be ...
|
|
WO/2004/060951A1 |
The present invention relates to a sulfur-containing polyureaurethane and a method of preparing said polyureaurethane. In an embodiment, the sulfur-containing polyureaurethane adapted to have a refractive index of at least 1.57, an Abbe ...
|
